Your browser doesn't support javascript.
loading
Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy.
Hercun, Julian; Kim, Grace E; Da, Ben L; Rotman, Yaron; Kleiner, David E; Chang, Richard; Glenn, Jeffrey S; Hoofnagle, Jay H; Koh, Christopher; Heller, Theo.
Afiliação
  • Hercun J; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kim GE; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Da BL; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Rotman Y; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kleiner DE; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Chang R; Clinical Center, National Institutes of Health, Bethesda, MD, USA.
  • Glenn JS; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Hoofnagle JH; Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Koh C; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Heller T; Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Aliment Pharmacol Ther ; 54(2): 176-182, 2021 07.
Article em En | MEDLINE | ID: mdl-34048594
ABSTRACT

BACKGROUND:

Hepatitis delta virus (HDV) infection is the most aggressive form of chronic viral hepatitis. Response rates to therapy with 1- to 2-year courses of pegylated interferon alpha (peginterferon) treatment are suboptimal.

AIMS:

To evaluate the long-term outcomes of patients with chronic hepatitis D after an extended course of peginterferon.

METHODS:

Patients were followed after completion of trial NCT00023322 and classified based on virological response defined as loss of detectable serum HDV RNA at last follow-up. During extended follow-up, survival and liver-related events were recorded.

RESULTS:

All 12 patients who received more than 6 months of peginterferon in the original study were included in this analysis. The cohort was mostly white (83%) and male (92%) and ranged in age from 18 to 58 years (mean = 42.6). Most patients had advanced but compensated liver disease at baseline, a median HBV DNA level of 536 IU per mL and median HDV RNA level of 6.86 log10 genome equivalents per mL. The treatment duration averaged 6.1 years (range 0.8-14.3) with a total follow-up of 8.8 years (range 1.7-17.6). At last follow-up, seven (58%) patients had durable undetectable HDV RNA in serum, and four (33%) cleared HBsAg. Overall, one of seven (14%) responders died or had a liver-related event vs four of five (80%) non-responders.

CONCLUSIONS:

With further follow-up, an extended course of peginterferon therapy was found to result in sustained clearance of HDV RNA and favourable clinical outcomes in more than half of patients and loss of HBsAg in a third.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite D Crônica Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Assunto da revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite D Crônica Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Aliment Pharmacol Ther Assunto da revista: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos